Cited by 82Hormonal and reproductive studiesDiabetes Management and ResearchDiabetes Treatment and Management

Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study

Open access
Haider, Karim Sultan, Haider, Ahmad, Saad, Farid, Doros, Gheorghe, Hanefeld, Markolf, Dhindsa, Sandeep, Dandona, Paresh, Traish, Abdulmaged·2020·Diabetes, Obesity and Metabolism

Abstract

Aims: To investigate whether testosterone therapy (TTh) in men with hypogonadism and type 2 diabetes mellitus (T2DM) improves glycaemic control and insulin sensitivity, and results in remission of T2DM. Material and Methods: A total of 356 men who had total testosterone levels ≤12.1 nmol/L (350 ng/dL) and symptoms of hypogonadism were included in the study and followed up for 11 years. All patients received standard diabetes treatment and 178 patients additionally received parenteral testosterone undecanoate 1000 mg every 12 weeks following an initial 6‐week interval. A control group comprised 178 hypogonadal patients who opted not to receive TTh. Results: Patients with hypogonadism and T2DM treated with testosterone had significant progressive and sustained reductions in fasting glucose, glycated haemoglobin (HbA1c) and fasting insulin over the treatment period. In the control group, fasting glucose, HbA1c and fasting insulin increased. Among the patients treated with testosterone 34.3% achieved remission of their diabetes and 46.6% of patients achieved normal glucose regulation. Of the testosterone‐treated group, 83.1% reached the HbA1c target of 47.5 mmol/mol (6.5%) and 90% achieved the HbA1c target of 53.0 mmol/mol (7%). In contrast, no remission of diabetes or reductions in glucose or HbA1c levels were noted in the control group. There were fewer deaths, myocardial infarctions, strokes and diabetic complications in the testosterone‐treated group. Conclusions: Long‐term TTh in men with T2DM and hypogonadism improves glycaemic control and insulin resistance. Remission of diabetes occurred in one‐third of the patients. TTh is potentially a novel additional therapy for men with T2DM and hypogonadism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14122

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Haider et al. reported in a prospective registry study over 11 years in 178 men with lowered serum testosterone, that testosterone treatment was associated with type 2 diabetes remission in 34.3% of patients.

    “Moreover, Haider et al. reported in a prospective registry study over 11 years in 178 men with lowered serum testosterone, that testosterone treatment was associated with type 2 diabetes remission in 34.3% of patients. 95”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Haider, K. S., Haider, A., Saad, F., Doros, G., Hanefeld, M., Dhindsa, S., Dandona, P., & Traish, A.
Affiliations
  • Private Urology Practice Bremerhaven Germany
  • Gulf Medical University (AE)
  • Boston University (US)
  • Zentrum für klinische Studien GWT‐TU Dresden GmbH Dresden Germany
  • Saint Louis University (US)
  • Kaleida Health (US)
Corresponding author
Traish, Abdulmaged
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2020-07-15
Volume
22
Issue
11
Pages
2055-2068
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3036206394
Cited by
82
References
48
Citations by year
2026: 5 · 2025: 9 · 2024: 7 · 2023: 18 · 2022: 18 · 2021: 19 · 2020: 6
FWCI
11.50
Type
journal article
Language
en
Open access
Locations
  • Diabetes Obesity and Metabolism (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Bayer
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
testosterone undecanoate, testosterone replacement therapy, type 2 diabetes remission, hypogonadism, glycemic control, insulin sensitivity, insulin resistance, HbA1c, fasting blood glucose, men, long-term treatment outcomes, cardiovascular events
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypogonadism, Male, Registries, Testosterone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review